Epidemiology of inhibitor development in haemophilia A patients treated with virus-inactivated plasma-derived clotting factor concentrates

Vox Sanguinis

Volumn 77, Issue SUPPL. 1, 1999, Pages 3-8

  Kreuz, Wolfhart ^a   Escuriola Ettingshausen, Carmen ^a   Martinez Saguer, Inmaculada ^a   Kaiml, Monika ^a   Kornhuber, Bernhard ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING INHIBITOR; NEUTRALIZING ANTIBODY;

CONFERENCE PAPER; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; VIRUS INACTIVATION;

BLOOD COAGULATION FACTORS; CHILD, PRESCHOOL; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INCIDENCE; INFANT; ISOANTIBODIES; PREVALENCE;

EID: 0032836392     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056704     Document Type: Conference Paper

References (24)

1. Hoyer LW: The incidence of factor VIII inhibitors in patients with severe hemophilia A; in Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GCI (eds): Inhibitors to coagulation factors. New York, Plenum Press, 1995; pp. 35-45.
2. Kreuz W, Escuriola-Ettingshausen C, Martinez-Saguer I, Güngör T, Kornhuber B: Epidemiology of Inhibitors in Haemophilia A. Vox Sang 1996;70(suppl 1):2-8.
3. Gill FM: The natural history of factor VIII inhibitors in patients with haemophilia A. Prog Clin Biol Res 1984;150:19-29.
4. Rasi V, Ikkala E: Haemophiliacs with factor VIII inhibitors in Finland: Prevalence, incidence and outcome. Br J Haematol 1990;76: 369-371.
5. DeBiasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, DeBiasi D: Incidence of factor VIII inhibitor development in haemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994;71:544-547.
6. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Güngör T, Krackhardt B, Kornhuber B: Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-598.
7. McMillan CW, Shapiro SS, Whithurst D, Hoyer LW, Rao V, Lazerson J and the Hemophilia Study Group: The natural history of factor VIII:C inhibitors in patients with hemophilia A. A National Cooperative Study: Observations on the initial development of factor VIII:C inhibitors. Blood 1988;71:344-348.
8. Lusher JM, Salzman PM and the Monoclate® Study Group: Viral safety and inhibitor development associated with factor VIII:C ultra-purified from plasma in haemophiliacs previously unexposed to factor VIII:C concentrate. Semin Haematol 1990;27:1-7.
9. Sultan Y and the French Haemophilia Study Group: Prevalence of inhibitors in a population of 3,435 haemophilia patients in France. Thromb Haemost 1992;67:600-602.
10. Schwarzinger I, Pabinger I, Korninger C, Haschke F, Kundi M, Niessner H, Lechner K: Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987;24: 241-245.
11. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher J, Glader B, Aledort L: Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993;342:462-464.
12. Ljung R, Petrini P, Lindgren A, Tengborn L, Nilsson I: Factor VIII and factor IX inhibitors in haemophiliacs (letter). Lancet 1992;339: 1550.
13. Lusher JM: Viral safety and inhibitor development associated with monoclonal antibody-purified FVIII:C. Ann Hematol 1991;63:138-141.
14. Kreuz W, Auerswald G, Budde U, Lenk H, Klose HJ and the GTH-PUP-Study-Group: Inhibitor incidence in previously untreated patients (PUPs) with haemophilia A and B. Ann Hematol 1998;76(Suppl I):15 (abstr. V33).
15. Inhibitor Incidence in previously untreated hemophilia patients. A prospective, multicentre study of the Paediatric Study Group of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Study protocol.
16. Aledort L: Proposal for a standardized protocol for PUP studies to screen for inhibitor formation. SSC for FVIII and IX of the International Society on Thrombosis and Haemostasis, Munich 1992.
17. Escuriola Ettingshausen C, Gringeri A, Budde U, Mannucci PM, Kreuz W: Inhibitor development in previously untreated patients (PUPs) with hemophilia A treated with Kogenate®: G.I.P.S.I. - German-Italian PUP study on inhibitor development. Blood 1997;90(Suppl 1): 156-157 (abstr).
18. Lusher J, Arkin S, Hurst D et al: Recombinant FVIII (Kogenate®) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years.Thromb Haemost (1997);ISTH Florence (abstr 664).
19. Gruppo R, Bray GL, Schroth P, Perry M, Gomperts ED: Safety and immunogenicity of recombinant factor VIII (Recombinate®) in previously untreated patients (PUPs): a 6.5 year update. Thromb Haemost (1997);ISTH Florence (abstr 663).
20. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E: The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specifity and reliability. Thromb Haemost 1995;73:247-251.
21. Klinge J, Auerswald G, Budde U, Klose H, Kreuz W, Lenk H, Scandella D and the Pediatric group of the GTH: Antibody formation to factor VIII in hemophilia A patients is more frequent than suggested by the Bethesda assay. Ann Hematol 1998;76(suppl I):15 (abstr V34).
22. Schwaab R, Brackmann HH, Meyer C et al: Haemophilia A: Mutation type determines risk of inhibitor formation. Thromb Haemost 1995; 74:1402-1406.
23. Oldenburg J, Picard JK, Schwaab R, Brackmann HH, Tuddenham EGD, Simpson E: HLA genotypes of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997;77(2):238-242.
24. Addiego J, Kasper C, Abildgaard C, Hilgartner M, Lusher M, Glader B, Aledort L: Inhibitors in factor VIII deficient hemophiliacs: Comparison of frequency based upon treatment. Blood 1992;80(suppl 1):57, (abstr 217).